Low Float (AIMD) Makes it to Our Potential Breakout Watchlist on Approx 9% Move Out of the Gate

Breaking Now: Immediately add Ainos, Inc. (NASDAQ: AIMD) to Your Watchlist This Morning! Don’t Miss Out on This One! Take a Look at (AIMD) Now or You Could Miss It! High Insider Confidence: With over 81% insider ownership, Ainos, Inc. (NASDAQ: AIMD)’s leadership strongly believes in the company's growth and future potential. Limited Public Float: Less than 1.5M shares available, making Ainos, Inc. (NASDAQ: AIMD) one company to keep a close eye on.  Innovative Product Pipeline: VELDONA®, a low-dose oral interferon with FDA orphan status, is set to address rare, difficult-to-treat conditions. AI-Driven Healthcare Solutions: Ainos, Inc. (NASDAQ: AIMD)’s AI-powered point-of-care testing and AI Nose technology put it at the forefront of healthcare innovation. FDA-Backed Regulatory Advantages: VELDONA® benefits from fast-tracked approval and market exclusivity due to its FDA orphan status. Don’t Miss Ainos, Inc. (NASDAQ: AIMD)! Take 2 Minutes Now to Connect with Us on all of Our No-Cost Platforms! (See instructions below) October 2, 2024 Dear Reader, Don’t wait on this one. Ainos, Inc. (NASDAQ: AIMD) just made it to our potential breakout watchlist on an approximate 9% early move.  Do you have (AIMD) pulled up yet? Ainos, Inc. (NASDAQ: AIMD) reached pre-market high of $0.5199 which is important because it surpassed several key moving averages including the 5-day at .04928 and the 20-day at 0.5082. Keep a close eye on Ainos, Inc. (NASDAQ: AIMD) along with the following moving averages: 5-Day : 0.4928 20-Day: 0.5082 50-Day: 0.5830 100-Day: 0.7322 200-Day: 1.0247 Year-to-Date: 0.9542 Ainos, Inc. (NASDAQ: AIMD), headquartered in San Diego, is a cutting-edge healthcare company making strides in the world of AI-powered solutions.  With a limited float of fewer than 1.5M shares and over 81% insider ownership, it’s clear the people closest to the company believe in its potential.  This combination of next-gen technology and strong internal backing positions Ainos as a standout in the healthcare sector. At the heart of Ainos, Inc. (NASDAQ: AIMD)’s progress is their revolutionary product, VELDONA®, a low-dose oral interferon therapy that’s already earned orphan designation from the U.S. FDA. This recognition highlights VELDONA®’s potential to address rare and difficult-to-treat conditions. Currently, Ainos is spearheading a groundbreaking clinical trial at National Taiwan University Hospital.  The study is focused on using VELDONA® to treat HIV-related oral warts, a common and debilitating complication among HIV-positive patients. This clinical trial is a major milestone for the company.  It not only underscores the potential of VELDONA® as a therapeutic option for HIV-positive individuals but also fast-tracks the dr-ug's path to commercialization, thanks to its orphan designation.  The trial will assess the safety and efficacy of VELDONA® in combination with standard antiretroviral therapy, with results expected to make waves in the medical community. With over 39M people living with HIV globally, this is a significant area of unmet need.  The FDA’s orphan status offers VELDONA® several regulatory advantages, including extended market exclusivity and fast-tracked approval processes, giving Ainos, Inc. (NASDAQ: AIMD) a competitive edge in bringing this much-needed therapy to market. Ainos, Inc. (NASDAQ: AIMD) is not stopping there.  Their AI-powered point-of-care testing (POCT) platform, driven by their proprietary AI Nose technology, aims to further empower individuals with accessible, real-time healthcare solutions.  This diversified portfolio, which combines AI with healthcare, positions Ainos at the forefront of the next wave of health-tech innovation. With fewer than 1.5M shares available and insider confidence at a remarkable 81%, the time to take a look at Ainos, Inc. (NASDAQ: AIMD) is now. Ainos, Inc. (NASDAQ: AIMD) is a company actively advancing innovative healthcare solutions with significant market potential.  Their recent clinical trial initiation represents not just a step forward, but a leap toward addressing global health challenges through AI and novel therapies. Make sure Ainos, Inc. (NASDAQ: AIMD) is on your watchlist today. In the meantime,  I’m urging you to connect with us on all of our no-cost platforms so you can receive our reports up to 10X faster than email alone. If you haven't already, please take a moment to set up these platforms now: SMS: To make sure you’re signed up for our no-cost SMS Alerts, which are up to 10X faster than email, click here. Telegram Channel: Click now to join our no-cost Telegram Channel for real-time updates. WhatsApp: Or if you prefer WhatsApp, click here to join our real-time Market Chatter. All three of these should take less than 3 minutes to connect but could give you a massive advantage in the market.  Make no mistake –  Ainos, Inc. (NASDAQ: AIMD) needs to be #1 on your watchlist this morning (October 2, 2024) or you could miss it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer We have not been compensated for October 2, 2024’s profile on (AIMD:US). We own zero shares of (AIMD:US).

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice